Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Wiemer

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Chemmedchem|May 27, 2020
Structure-Activity Relationships of Butyrophilin 3 LigandsAndrew J Wiemer
ACS Pharmacology & Translational Science|August 22, 2020
Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir ParadigmAndrew J Wiemer
Drugs in R&D|July 1, 2024
Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic ConsiderationsIna Lami, Andrew J Wiemer
Current Protocols|July 7, 2021
Generation of Single-Chain Variable Fragment (scFv) Libraries for Use in Phage DisplayMegan A Schladetsch, Andrew J Wiemer
Topics in Current Chemistry|November 14, 2014
Prodrugs of phosphonates and phosphates: crossing the membrane barrierAndrew J Wiemer, David F Wiemer
Biochemical Pharmacology|April 1, 2014
Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonistsDavid F Wiemer, Andrew J Wiemer
Methods in Molecular Biology (Clifton, N.J.)|September 13, 2011
Live imaging of LFA-1-dependent T-cell motility and stop signalsAndrew J Wiemer, Sarah Wernimont, Anna Huttenlocher
Biochemical Pharmacology|November 5, 2018
A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigensChia-Hung Christine Hsiao, Andrew J Wiemer
Trends in Pharmacological Sciences|December 4, 2025
Molecular glues evolve from serendipity to rational designPrincy Shrivastav, Rohit Singh, Andrew J Wiemer
STAR Protocols|June 9, 2022
Generation of effector Vγ9Vδ2 T cells and evaluation of their response to phosphoantigen-loaded cellsChia-Hung Christine Hsiao, Andrew J Wiemer
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Chemmedchem|May 27, 2020
Structure-Activity Relationships of Butyrophilin 3 LigandsAndrew J Wiemer
ACS Pharmacology & Translational Science|August 22, 2020
Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir ParadigmAndrew J Wiemer
Drugs in R&D|July 1, 2024
Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic ConsiderationsIna Lami, Andrew J Wiemer
Current Protocols|July 7, 2021
Generation of Single-Chain Variable Fragment (scFv) Libraries for Use in Phage DisplayMegan A Schladetsch, Andrew J Wiemer
Topics in Current Chemistry|November 14, 2014
Prodrugs of phosphonates and phosphates: crossing the membrane barrierAndrew J Wiemer, David F Wiemer
Biochemical Pharmacology|April 1, 2014
Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonistsDavid F Wiemer, Andrew J Wiemer
Methods in Molecular Biology (Clifton, N.J.)|September 13, 2011
Live imaging of LFA-1-dependent T-cell motility and stop signalsAndrew J Wiemer, Sarah Wernimont, Anna Huttenlocher
Biochemical Pharmacology|November 5, 2018
A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigensChia-Hung Christine Hsiao, Andrew J Wiemer
Trends in Pharmacological Sciences|December 4, 2025
Molecular glues evolve from serendipity to rational designPrincy Shrivastav, Rohit Singh, Andrew J Wiemer
STAR Protocols|June 9, 2022
Generation of effector Vγ9Vδ2 T cells and evaluation of their response to phosphoantigen-loaded cellsChia-Hung Christine Hsiao, Andrew J Wiemer
Pageof 7